Xybion Digital Inc. and Certara, Inc. announced that they have signed a partnership agreement to bring new integrated solutions in the Nonclinical R&D space with Xybion's Nonclinical LIMS-Pristima XD and Certara's SEND Explorer, Pinnacle 21 and other software products. Today's lab operations are becoming increasingly digitized. This creates vast amounts of data that can be utilized for predictive outcomes.

However, siloed technology products used in these labs are not able to create that value. Xybion and Certara join hands to remove some of these barriers by integrating their products to plan and execute studies and manage, analyze, and visualize data to accelerate predicting drug safety and efficacy. Pristima®?

XD, preclinical LIMS software, creates an end-to-end digital laboratory execution environment with the flexibility of managing various study types for GLP and non-GLP labs. Certara's SEND explorer?? Product Family is a best-of-class data warehousing and visualization application capable of consuming nonclinical study data in a wide variety of formats including SEND (Standard for Exchange of Nonclinical) datasets, static spreadsheet formats, and direct connection to Xybion's Pristima data collection system (or the Savante data repository) allowing organizations to monitor in-progress studies and visualize/query data from ongoing and/or completed studies in the assessment of compound safety.

Together, Certara and Xybion products provide the following capabilities: Study planning; Protocol management; Study execution and data collection; Quality, compliance, and deviation management; Data Management; Visualizations for ongoing studies; Multi-study visualizations; patterns and trends within or across studies; Anticipate regulatory concerns; Support scientific collaboration and communicate findings; Leverage historical data in drug development decision-making; Data validation and SEND submission.